2020 Corporate Social Responsibility Report

Company: FOSUN PHARMA (2196)
Year: 2020
Published: 2021-04-19
Status: Processed
View Report

Extracted ESG KPIs

KPIs are organized by ESG aspects.

The types of emissions and respective emissions data.

Indicator Unit 2016 2017 2018 2019 2020 Report Pages
Ammonia nitrogen ton/year 60.55 486 254 130 88.5 100
Ammonia nitrogen intensity kg/RMB10000 0.262 0.0414 0.102 0.046 0.03 85
COD ton/year 490 841 847 778 655 100
COD emission intensity kg/RMB10000 of output value 0.33 0.45 0.34 0.27 0.22 100, 126
COD emission intensity (actual in 2020) kg/RMB10000 of output value 0.22 100
COD emissions intensity kg/RMB10000 0.33 0.45 0.34 0.27 0.22 85
Emission of COD tons/year 847 778 655 126
Emission of NH3-N tons/year 254 130 88 126
Emission of nitrogen oxides tons/year 251 258 158 126
Emission of particles tons/year 44 36 37 126
Emission of sulphur oxides tons/year 279 134 105 126
Nitrogen oxides emission ton/year 466 239 251 258 158 102
Nitrogen oxides emission - Healthcare services ton/year 1.9 102
Nitrogen oxides emission - Medical devices and diagnosis ton/year 0.3 102
Nitrogen oxides emission - Pharmaceutical manufacturing and R&D ton/year 155.8 102
Nitrogen oxides emission - Total ton/year 158 102
Non-methane total hydrocarbons emission ton/year 24.2 102
Non-methane total hydrocarbons emission - Pharmaceutical manufacturing and R&D ton/year 24.2 102
Non-methane total hydrocarbons emission - Total ton/year 24.2 102
Particles emission ton/year 19 41 44 36 37 102
Particles emission - Healthcare services ton/year 0.2 102
Particles emission - Pharmaceutical manufacturing and R&D ton/year 36.5 102
Particles emission - Total ton/year 36.7 102
Sulfur oxides emission ton/year 485 245 279 134 105 102
Sulfur oxides emission - Pharmaceutical manufacturing and R&D ton/year 105 102
Sulfur oxides emission - Total ton/year 105 102
Total ammonia nitrogen emission ton 466 239 251 258 158 85
Total sulfur oxides emission ton 485 245 279 134 105 85
VOC emissions tons 2.42 102

Direct (Scope 1) and energy indirect (Scope 2) greenhouse gas emissions (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 2019 2020 Report Pages
Ammonia nitrogen emission intensity kg/RMB10000 of output value 0.041 0.262 0.102 0.046 0.03 100, 126
Ammonia nitrogen emission intensity (actual in 2020) kg/RMB10000 of output value 0.03 100
Carbon emission intensity ton/RMB10000, ton/RMB10000 of output value, tons/RMB10000 of output value 0.6 0.54 0.41 0.35 0.27 84, 92, 96, 126
Direct greenhouse gas emissions ton 288447 338285 397106 381580 225622 96
Indirect greenhouse gas emissions ton 457732 484501 389265 376563 602236 96
Total carbon emission ton/year 786371 758143 827858 126
Total carbon emissions ton 746179 822766 786371 758143 827858 96
Wanbang Jinqiao carbon emissions reduction tons 2777 97

Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 2019 2020 Report Pages
Antibiotic utilization rate decrease % -17.73 49
Hazardous waste tons/year 2683.2 4320.8 5914.5 126
Hazardous waste (Fosun Pharma Group) tons 1626.8 2396.9 2683.2 4320.8 5914.5 104
Hazardous waste (Healthcare services) tons 855.6 104
Hazardous waste (Medical devices and diagnosis) tons 45.7 104
Hazardous waste (Pharmaceutical manufacturing and R&D) tons 5013.2 104
Hazardous waste (Total) tons 5914.5 104
Hazardous waste (total) tons 5914.5 104
Hazardous waste intensity kg/RMB10000 of output value 1.08 1.51 1.95 126
Hazardous waste intensity (Fosun Pharma Group) kg/RMB10000 of output value 1.11 1.29 1.07 1.51 1.95 104
Hazardous waste subject to landfill disposal tons 411.1 104
Hazardous waste treated in other ways tons 129.1 104
Number of member enterprises passed clean production certification enterprises 13 86
Solid waste intensity kg/RMB10000 55.27 48 34.43 25.74 16.26 84
Total wastewater tons/year 7565178 7091033 6505479 126
Total wastewater discharge ton/year 6785400 7315890 7565178 7091033 6505479 100

Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 2019 2020 2020 target Report Pages
Domestic waste (Healthcare services) tons 3623.3 104
Domestic waste (Medical devices and diagnosis) tons 102.3 104
Domestic waste (Pharmaceutical manufacturing and R&D) tons 2585.8 104
Domestic waste (Total) tons 6311.3 104
Glass packaging material consumed by Fosun Pharma Group ton 11050.5 6209.9 106
Industrial solid waste (non-hazardous) (Medical devices and diagnosis) tons 150.7 104
Industrial solid waste (non-hazardous) (Pharmaceutical manufacturing and R&D) tons 36909.6 104
Industrial solid waste (non-hazardous) (Total) tons 37060.2 104
Internal recycling rate of packaging materials by Fosun Pharma Group 0.2% 106
Sewage discharge intensity ton/RMB10000, ton/RMB10000 of output value 4.64 3.95 3.04 2.48 2.15 85, 100
Sewage discharge intensity (actual in 2020) ton/RMB10000 of output value 2.15 100
Sewage discharge intensity (target for 2020) ton/RMB10000 of output value 3.25 100
Total solid waste tons/year 85796.6 73583.6 49286 126
Total solid waste (Fosun Pharma Group) tons 80848 88967 85796.6 73538.6 49286 104
Total solid waste generated by Group's domestic enterprises tons 49286 104
Total solid waste intensity kg/RMB10000 of output value 34.43 25.74 16.26 38.69 104, 126
Total solid waste intensity (Fosun Pharma Group) kg/RMB10000 of output value 55.27 48.01 34.36 25.74 16.26 104

Description of emissions target(s) set and steps taken to achieve them.

Indicator Unit 2020 Report Pages
Ammonia nitrogen emission intensity (target for 2020) kg/RMB10000 of output value 0.039 100
COD emission intensity (target for 2020) kg/RMB10000 of output value 0.25 100
Carbon emission reduction of energy-saving projects tons 7400 92
Greenhouse gas emissions reduced tons 7399 9
NOx emissions reduction compared to 2016 tons 308 9
SO2 emissions reduction compared to 2016 tons 380 9

Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.

Indicator Unit 2020 Report Pages
External recycling rate of packaging materials by Fosun Pharma Group 96.4% 106
Hazardous waste incinerated tons 565.2 104
Hazardous waste recycled tons 91.2 104
Industrial solid waste recycled rate 82% 104
VOC removal rate % >90 102
VOC terminal processing equipment coverage 100% 102

Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 2019 2020 Report Pages
Chemo Biopharm Power consumption in October 2019 kWh 700000 97
Chemo Biopharm Power consumption in October 2020 kWh 500000 97
Chemo Biopharm Power consumption in September 2019 kWh 600000 97
Chemo Biopharm Power consumption in September 2020 kWh 400000 97
Chemo Biopharm Steam data in October 2019 Ton 700 97
Chemo Biopharm Steam data in October 2020 Ton 500 97
Chemo Biopharm Steam data in September 2019 Ton 600 97
Chemo Biopharm Steam data in September 2020 Ton 400 97
Comprehensive energy consumption intensity GJ/RMB10000 4.43 3.51 3.11 2.65 2.53 84
Comprehensive energy intensity GJ/RMB10000 of output value 2.53 92
Diesel consumption, Fosun Pharma Group litre 2131202 96
Diesel consumption, Healthcare services litre 78886 96
Diesel consumption, Medical devices and medical diagnosis litre 402462 96
Diesel consumption, Pharmaceutical manufacturing and R&D litre 1649854 96
Direct energy consumption GJ/year 3281592 3839551 4466930 4344819 26049590 96, 126
Energy consumption other than electricity GJ/year 5394870 5304416 126
Fuel oil consumption, Fosun Pharma Group ton 4111 96
Fuel oil consumption, Pharmaceutical manufacturing and R&D ton 4111 96
Gasoline consumption, Fosun Pharma Group litre 487309 96
Gasoline consumption, Healthcare services litre 143586 96
Gasoline consumption, Medical devices and medical diagnosis litre 132191 96
Gasoline consumption, Pharmaceutical manufacturing and R&D litre 211532 96
Indirect energy consumption GJ/year 2500429 2657132 2368332 3231371 5050819 96, 126
Liquefied gas consumption, Fosun Pharma Group kg 44210 96
Liquefied gas consumption, Healthcare services kg 2250 96
Liquefied gas consumption, Medical devices and medical diagnosis kg 5295 96
Liquefied gas consumption, Pharmaceutical manufacturing and R&D kg 36665 96
Natural gas consumption, Fosun Pharma Group m³ 18794063 96
Natural gas consumption, Healthcare services m³ 1250317 96
Natural gas consumption, Medical devices and medical diagnosis m³ 227510 96
Natural gas consumption, Pharmaceutical manufacturing and R&D m³ 17316236 96
Raw coal consumption, Fosun Pharma Group ton 79958 96
Raw coal consumption, Pharmaceutical manufacturing and R&D ton 79958 96
Steam consumption, Fosun Pharma Group ton 731881 96
Steam consumption, Pharmaceutical manufacturing and R&D ton 731881 96
Total electricity consumption kWh/year 47875186 51322112 655108860 631436019 637986028 96, 126
Total electricity consumption, Fosun Pharma Group kWh/year 637986028 96
Total electricity consumption, Healthcare services kWh/year 40538437 96
Total electricity consumption, Medical devices and medical diagnosis kWh/year 15392998 96
Total electricity consumption, Pharmaceutical manufacturing and R&D kWh/year 582054593 96
Total energy consumption GJ/year 5581931 6496683 7753262 7576550 7655768 96, 126
Total energy consumption intensity GJ/RMB10000 of output value 4.43 3.51 3.11 2.65 2.53 96
Total energy intensity GJ/RMB10000 of output value 3.11 2.65 2.53 126

Water consumption in total and intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 2019 2020 Report Pages
Decrease in total water consumption compared to 2019 m³ 146109 98
Decrease in total water consumption compared to 2019 (percentage) % -1.53 98
Decrease in water consumption intensity compared to 2019 % -6.9 98
Total water consumption m³/year 9959415 9527927 9381818 126
Total water consumption of Fosun Pharma Group m³, m³/year 8769376 9515697 9959415 9527927 93818181 98, 99
Total water saving m³ 282923 98
Wastewater discharge intensity tons/RMB10000 of output value 3.04 2.48 2.15 126
Water consumption intensity m³/RMB10000, m³/RMB10000 of output value, m³/RMB10000 of output value (target for 2020), m³/year 5.99 5.14 3.99 3.33 3.1 84, 98, 126
Water consumption intensity of Fosun Pharma Group m³/RMB10000 of output value 5.99 5.14 3.99 3.33 3.1 99

Description of energy use efficiency target(s) set and steps taken to achieve them.

Indicator Unit 2020 Report Pages
Aohong Pharma electricity saved through air compressor optimization kWh 228600 97
Aohong Pharma natural gas saved by water recycling tons 4623 97
Aohong Pharma water saved by water recycling m³ 5590 97
Electricity saved million kWh 7.13 9
Guilin Pharma natural gas saved m³ 566000 97
Natural gas saved thousand cubic meters 950 9
Percentage of total water consumption saved by cooling tower water charging (Fosun Pharma Group) 6.54% 99
Wanbang Jinqiao steam consumption reduction in workshop tons 5000 97
Water charging amount of cooling tower saved (Fosun Pharma Group) tons 613619 99

Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.

Indicator Unit 2020 Report Pages
Total sewage discharge decrease compared with 2016 tons 279921 100
Total sewage discharge percentage decrease compared with 2016 -4.1% 100
Water-saving volume - Aleph 10000 m³ 0.12 98
Water-saving volume - Aohong Pharma 10000 m³ 0.642 98
Water-saving volume - Carelife Pharma 10000 m³ 2.556 98
Water-saving volume - Chemio Biopharm 10000 m³ 0.7 98
Water-saving volume - Eye Pharma 10000 m³ 0.464 98
Water-saving volume - Foshan Chancheng Central Hospital 10000 m³ 5.1 98
Water-saving volume - Gland Pharma 10000 m³ 2.044 98
Water-saving volume - Guilin Pharma 10000 m³ 1.729 98
Water-saving volume - Hexin Pharma 10000 m³ 0.26 98
Water-saving volume - Hongqi Pharma 10000 m³ 1.634 98
Water-saving volume - Huanghe Pharma 10000 m³ 0.228 98
Water-saving volume - Laishi Transfusion 10000 m³ 0.5 98
Water-saving volume - Shanghai Henlius 10000 m³ 5.261 98
Water-saving volume - Wanbang Jinqiao 10000 m³ 4.872 98
Water-saving volume - Wanbang Pharma 10000 m³ 0.375 98
Water-saving volume - Yaopharma 10000 m³ 0.1 98
Water-saving volume - Zhaohai Pharma 10000 m³ 1.387 98

Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.

Indicator Unit 2019 2020 Report Pages
Decrease in packaging materials consumption compared to 2019 ton -3375 106
Metal packaging material consumed by Fosun Pharma Group ton 468.4 352.7 106
Others packaging material consumed by Fosun Pharma Group ton 68.4 66.4 106
Packaging materials recycled externally by Fosun Pharma Group ton 19519 106
Packaging materials recycled for internal use by Fosun Pharma Group ton 46.5 106
Paper packaging material consumed by Fosun Pharma Group ton 10999.9 8550.1 106
Plastic packaging material consumed by Fosun Pharma Group ton 2715.3 1841 106
Rubber packaging material consumed by Fosun Pharma Group ton 854 468.1 106
Total consumption of packaging materials by Fosun Pharma Group ton 20237 106
Wood packaging material consumed by Fosun Pharma Group ton 181 2.24 106

Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.

Indicator Unit 2016 2017 2018 2019 2020 Report Pages
Environmental protection investment RMB'0000 3.346 7.348 15.952 12.483 12.079 88
Investment in environmental protection RMB'000, RMB/10000 3346 7348 15952 12483 1079 84, 126
OPEX lean projects annual saving million RMB 51.45 9

Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.

Indicator Unit 2018 2019 2020 Report Pages
Employment rate of ethnic minority employees % 2.03 3.57 2.9 125
Employment rate of people with disabilities % 0.23 0.24 0.22 125
Group CMI (Case Mix Index) increase % 9.54 49
Labor contract conclusion rate 100% 100% 100% 125
Number of R&D staff 1797 2147 2258 125
Number of beds in member hospitals of Fosun Healthcare Group 4610 9
Number of disabled employees 74 72 71
Number of employees aged 16-20 140 50 29 65
Number of employees aged 30-40 9768 9975 9828 65
Number of employees aged 40-50 9964 11439 12584 65
Number of employees aged 50-55 5886 6441 6383 65
Number of employees aged 55-60 1486 1894 1953 65
Number of employees aged above 60 711 1337 1118 65
Number of employees in Central China 3853 4081 4718 65
Number of employees in Eastern China 11094 12590 10637 65
Number of employees in Northern China 280 292 1249 65
Number of employees in Northwest China 1869 2584 2540 65
Number of employees in Southern China 4812 4929 5570 65
Number of employees in Southwest China 1293 1629 1879 65
Number of employees overseas 4864 5326 5253 65
Number of employees with doctor degree 328 350 411 65
Number of employees with junior college education 7183 8236 8516 65
Number of employees with master degree 2922 3312 3613 65
Number of employees with secondary school education and below 8675 9230 8389 65
Number of employees with undergraduate degree 9137 10425 11329 65
Number of ethnic minority employees 574 1114 934 125
Number of female employees 14703 15461 71
Number of minority employees 1114 934 71
Proportion of disabled employees 0.24% 0.22% 71
Proportion of female employees 47.12% 47.93% 71
Proportion of minority employees 3.57% 2.90% 71
Total number of employees person 28245 31370 32258 64, 125
Total number of employees by age group 28445 31770 32258 65
Total number of employees by education 28245 31770 32258 65
Total number of employees with master and doctor degrees 3250 3662 4024 125
Total number of female employees person 13273 14830 15461 64, 125
Total number of male employees person 14972 16540 16797 64, 125
Union coverage rate 100% 100% 100% 125

Employee turnover rate by gender, age group and geographical region.

Indicator Unit 2018 2019 2020 Report Pages
Ration of female employee returning to work and job positions retained till after the completion of the maternity leave 100% 100% 100% 125
Staff loss rate 17.69% 16.13% 15.40% 71
Staff outflow rate 21.22% 17.70% 18.76% 71

Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.

Indicator Unit 2016 2017 2018 2019 2020 Report Pages
Loss time injury rate per million man-hour 0.226 0.343 0.313 126
Major injury case rate, Pharmaceutical manufacturing and R&D 0.047 74
Major injury case rate, Total 0.033 74
Major injury rate per million man-hour 0.22 0.039 0.038 0.033 74
Minor injury case rate, Healthcare services 0.407 74
Minor injury case rate, Pharmaceutical manufacturing and R&D 0.281 74
Minor injury case rate, Total 0.28 74
Minor injury rate per million man-hour 0.36 0.385 0.188 0.343 0.28 74
Number of recordable incident, Healthcare services 7 74
Number of recordable incident, Pharmaceutical manufacturing and R&D 23 74
Number of recordable incident, Total 30 74
Occupational hazard exposure rate 12.34% 12.66% 12.33% 126
Recordable incident rate per million man-hour 1.05 0.915 0.433 0.395 0.494 74
Recordable incident rate, Healthcare services 0.569 74
Recordable incident rate, Pharmaceutical manufacturing and R&D 0.538 74
Recordable incident rate, Total 0.494 74
Recordable injury rate per million man-hour 0.433 0.395 0.494 126

Lost days due to work injury.

Indicator Unit 2016 2017 2018 2019 2020 Report Pages
Lost time injury rate per million man-hour 0.58 0.415 0.226 0.343 0.313 74
Lost time injury rate, Healthcare services 0.407 74
Lost time injury rate, Pharmaceutical manufacturing and R&D 0.328 74
Lost time injury rate, Total 0.313 74
Lost time, Healthcare services hours 112 74
Lost time, Pharmaceutical manufacturing and R&D hours 684 74
Lost time, Total hours 796 74

Description of occupational health and safety measures adopted, and how they are implemented and monitored.

Indicator Unit 2016 2017 2018 2019 2020 Report Pages
Average hospital stay decrease % -1.53 49
Investment in health and safety RMB'000 3843 5801 6186 126
Number of member enterprises completed exchange of certification from OHSAS18001 to ISO45001 enterprises 4 86
Number of member enterprises passed third-party certification of ISO14001 and/or OHSAS18001 system enterprises 14 86
Number of member enterprises passed third-party review of national safety production standardization enterprises 21 86
Preventive antibiotics for Class I incisions decrease % -17.5 49
Safety investment RMB'0000 3.155 3.919 3.843 5.801 6.186 88
Total EHS training hours hours 237572 404227 434130 126

The percentage of employees trained by gender and employee category (e.g. senior management, middle management).

Indicator Unit 2018 2019 2020 Report Pages
Number of OPEX lean projects 325 9
R&D expenditure as percentage of sales revenue of pharmaceutical business 11.28% 33
R&D expenditures YoY increase % 15.59 9
R&D expenditures for 2020 (including capitalized expenditures) billion RMB 4.003 9
R&D expense RMB100 million 10.26 20.41 27.95 33
R&D investment (including capitalized investment expense) RMB100 million 25.06 34.63 40.03 33
R&D investment (including capitalized investment expenses) RMB100 million 25.07 34.63 40.03 125
R&D investment in pharmaceutical manufacturing segment RMB billion 3.67 33
Training for Senior Management - Number of trainees person 376 1193 482 67
Training for Senior Management - Total training time hour 15412 33356 20712 67
Training for employees other than senior management - Number of trainees person 25144 30012 30260 67
Training for employees other than senior management - Total training time hour 839581 960008 646849 67

The average training hours completed per employee by gender and employee category.

Indicator Unit 2018 2019 2020 Report Pages
Average Training Hours Per Person - All employees hours/person 34 31 21 67
Average Training Hours Per Person - Female employees hours/person 37 28 20 67
Average Training Hours Per Person - Male employees hours/person 32 34 21 67
EHS training hours per employee hours 9.42 14.65 14.99 126
EHS training times per employee times 2.5 2.5 5.47 126
Total Training Expenses RMB'000 993 1480 904 67
Total training hours man-hour 854993 993364 667561 125

Number of suppliers by geographical region.

Indicator Unit 2020 Report Pages
Number of suppliers in Anhui (Domestic Member Enterprises of Fosun Pharma) 108 59
Number of suppliers in Beijing (Domestic Member Enterprises of Fosun Pharma) 148 59
Number of suppliers in Chongqing (Domestic Member Enterprises of Fosun Pharma) 117 59
Number of suppliers in Foreign suppliers (Domestic Member Enterprises of Fosun Pharma) 308 59
Number of suppliers in Fujian (Domestic Member Enterprises of Fosun Pharma) 34 59
Number of suppliers in Gansu (Domestic Member Enterprises of Fosun Pharma) 13 59
Number of suppliers in Guangdong (Domestic Member Enterprises of Fosun Pharma) 379 59
Number of suppliers in Guangxi (Domestic Member Enterprises of Fosun Pharma) 71 59
Number of suppliers in Guizhou (Domestic Member Enterprises of Fosun Pharma) 6 59
Number of suppliers in Hainan (Domestic Member Enterprises of Fosun Pharma) 13 59
Number of suppliers in Hebei (Domestic Member Enterprises of Fosun Pharma) 158 59
Number of suppliers in Heilongjiang (Domestic Member Enterprises of Fosun Pharma) 21 59
Number of suppliers in Henan (Domestic Member Enterprises of Fosun Pharma) 56 59
Number of suppliers in Hong Kong, Macao, Taiwan (Domestic Member Enterprises of Fosun Pharma) 10 59
Number of suppliers in Hubei (Domestic Member Enterprises of Fosun Pharma) 82 59
Number of suppliers in Hunan (Domestic Member Enterprises of Fosun Pharma) 201 59
Number of suppliers in Inner Mongolia (Domestic Member Enterprises of Fosun Pharma) 16 59
Number of suppliers in Jiangsu (Domestic Member Enterprises of Fosun Pharma) 611 59
Number of suppliers in Jilin (Domestic Member Enterprises of Fosun Pharma) 30 59
Number of suppliers in Liaoning (Domestic Member Enterprises of Fosun Pharma) 45 59
Number of suppliers in Ningxia (Domestic Member Enterprises of Fosun Pharma) 8 59
Number of suppliers in Qinghai (Domestic Member Enterprises of Fosun Pharma) 5 59
Number of suppliers in Shaanxi (Domestic Member Enterprises of Fosun Pharma) 23 59
Number of suppliers in Shandong (Domestic Member Enterprises of Fosun Pharma) 237 59
Number of suppliers in Shanghai (Domestic Member Enterprises of Fosun Pharma) 668 59
Number of suppliers in Shanxi (Domestic Member Enterprises of Fosun Pharma) 27 59
Number of suppliers in Sichuan (Domestic Member Enterprises of Fosun Pharma) 99 59
Number of suppliers in Tianjin (Domestic Member Enterprises of Fosun Pharma) 59 59
Number of suppliers in Tibet (Domestic Member Enterprises of Fosun Pharma) 4 59
Number of suppliers in Xinjiang (Domestic Member Enterprises of Fosun Pharma) 15 59
Number of suppliers in Yunnan (Domestic Member Enterprises of Fosun Pharma) 13 59
Number of suppliers in Zhejiang (Domestic Member Enterprises of Fosun Pharma) 277 59
Number of suppliers involved in business for the year (Aleph) 24 59
Number of suppliers involved in business for the year (Aohong Pharma) 44 59
Number of suppliers involved in business for the year (Erye Pharma) 131 59
Number of suppliers involved in business for the year (Guilin Pharma) 158 59
Number of suppliers involved in business for the year (Hongqi Pharma) 116 59
Number of suppliers involved in business for the year (Shanghai Henlius) 34 59
Number of suppliers involved in business for the year (Wanbang Pharma) 958 59
Number of suppliers involved in business for the year (Yaopharma) 449 59

Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.

Indicator Unit 2020 Report Pages
Number of consistency evaluation projects 42 33
Number of suppliers under annual review (Aleph) 24 59
Number of suppliers under annual review (Aohong Pharma) 44 59
Number of suppliers under annual review (Erye Pharma) 113 59
Number of suppliers under annual review (Guilin Pharma) 158 59
Number of suppliers under annual review (Hongqi Pharma) 84 59
Number of suppliers under annual review (Shanghai Henlius) 34 59
Number of suppliers under annual review (Wanbang Pharma) 888 59
Number of suppliers under annual review (Yaopharma) 325 59
Number of suppliers under annual review / Number of suppliers involved in business for the year (Aleph) 100.0% 59
Number of suppliers under annual review / Number of suppliers involved in business for the year (Aohong Pharma) 100.0% 59
Number of suppliers under annual review / Number of suppliers involved in business for the year (Erye Pharma) 86.3% 59
Number of suppliers under annual review / Number of suppliers involved in business for the year (Guilin Pharma) 100.0% 59
Number of suppliers under annual review / Number of suppliers involved in business for the year (Hongqi Pharma) 72.4% 59
Number of suppliers under annual review / Number of suppliers involved in business for the year (Shanghai Henlius) 100.0% 59
Number of suppliers under annual review / Number of suppliers involved in business for the year (Wanbang Pharma) 92.7% 59
Number of suppliers under annual review / Number of suppliers involved in business for the year (Yaopharma) 72.4% 59

Percentage of total products sold or shipped subject to recalls for safety and health reasons.

Indicator Unit 2020 Report Pages
EU certification - APIs APIs 3 41
EU certification - aseptic production lines production lines 2 41

Number of products and service related complaints received and how they are dealt with.

Indicator Unit 2018 2019 2020 Report Pages
Average satisfaction of outpatients and inpatients in member hospitals of Fosun Healthcare Group % 95 9
Inpatient satisfaction - Foshan Chancheng Central Hospital % 98.6 49
Inpatient satisfaction - Jimin Cancer Hospital % 95.3 49
Inpatient satisfaction - Shenzhen Hengsheng % 95.2 49
Inpatient satisfaction - Suqian Zhongwu % 96.8 49
Inpatient satisfaction - Wenzhou Geriatrics % 96.7 49
Inpatient satisfaction - Wuhan Jihe % 96.1 49
Inpatient satisfaction - Yueyang Guangji % 94.2 49
Number of generic drug projects 121 33
Number of projects on innovative drugs, generic drugs, biosimilars and consistency evaluation at end of 2020 247 9
Outpatient satisfaction - Foshan Chancheng Central Hospital % 94.8 49
Outpatient satisfaction - Shenzhen Hengsheng % 90.4 49
Outpatient satisfaction - Suqian Zhongwu % 96.8 49
Outpatient satisfaction - Wenzhou Geriatrics % 98.2 49
Outpatient satisfaction - Wuhan Jihe % 95 49
Outpatient satisfaction - Yueyang Guangji % 97.8 49
Percentage of Class IV surgical patients increase % 19.53 49
Revenue for 2020 billion RMB 30.307 9
Revenue from healthcare services segment RMB'0000 256296.75 303992.27 317245.91 12
Revenue from medical devices and medical diagnosis segment RMB'0000 363886.91 373581.15 521723.03 12
Revenue from pharmaceutical manufacturing RMB'0000 1866134.51 2176587.34 2188022.46 12

Description of practices relating to observing and protecting intellectual property rights.

Indicator Unit 2018 2019 2020 Report Pages
China GMP certification - APIs APIs 67 41
China GMP certification - oral dosage production lines production lines 38 41
China GMP certification - sterile preparation production lines production lines 34 41
Japan PMDA certification - APIs APIs 3 41
Number of biosimilar projects 19 33
Number of licence-in innovative drug projects 13 33
Number of patent application 84 136 176 125
Number of patents granted 25 47 70 125
Number of pipeline projects (innovative drugs, generic drugs, biosimilars, consistency evaluation) 247 33
Number of self-developed biopharmaceutical innovative drug projects 25 33
Number of self-developed small-molecule innovative drug projects 18 33
US FDA certification - APIs APIs 13 41
US FDA certification - production lines of oral solid formation production lines 2 41
WHO certification - APIs APIs 4 41
WHO certification - injection production lines production lines 4 41
WHO certification - production line of oral solid formation production line 1 41

Description of quality assurance process and recall procedures.

Indicator Unit 2020 Report Pages
CE product certification - domestic medical devices and medical diagnosis subsidiaries enterprises with several products passed 6 41
ISO 13485:2016 certification - domestic medical devices and medical diagnosis subsidiaries enterprises passed 9 41
ISO9001:2015 certification - domestic medical devices and medical diagnosis subsidiaries enterprises passed 3 41
Number of innovative drug projects 56 33

Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.

Indicator Unit 2018 2019 2020 Report Pages
Under investigation items items 215 264 247 125

Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).

Indicator Unit 2018 2019 2020 Report Pages
Tax payment RMB'0000 269005 253276.76 248578.22 12
Tax payment in 2020 billion RMB 2.486 9
Total investment in targeted poverty alleviation in 2020 million RMB 11 9

Resources contributed (e.g. money or time) to the focus area.

Indicator Unit 2018 2019 2020 Report Pages
Number of children under 5 saved by artesunate for injection most 9
Number of patients saved by artesunate for injection (innovative drug) 30000000 9
Revenue RMB'0000 2491827.36 2588515.2 3030698.13 12
Social contribution per share RMB 3.97 4.59 4.83 125
Total donation to society in 2020 million RMB 40.38 9
Value of drugs donated in Rural Doctor Poverty Alleviation Project million RMB 3 9

The types of emissions and respective emissions data.

Standard Indicator Unit 2016 2017 2018 2019 2020
Airborne Particulate Matter (PM) Emissions ton/year 19 41 44 36 37
NOâ‚“ Emissions ton/year 466 239 251 258 158
SOâ‚“ Emissions ton/year 485 245 279 134 105

Direct (Scope 1) and energy indirect (Scope 2) greenhouse gas emissions (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2016 2017 2018 2019 2020
Direct GHG Emissions (Scope 1) ton 288447 338285 397106 381580 225622
Indirect Energy Emissions (Scope 2) ton 457732 484501 389265 376563 602236
Total GHG Emissions ton 746179 822766 786371 758143 827858
Total GHG Emissions Intensity (By Revenue) ton/RMB10000 0.6 0.54 0.41 0.35 0.27

Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2016 2017 2018 2019 2020
Hazardous Waste (Other Recovery) tons 129.1
Hazardous Waste Landfilling tons 411.1
Total Hazardous Waste tons 1626.8 2396.9 2683.2 4320.8 5914.5
Total Hazardous Waste Intensity (By Revenue) kg/RMB10000 of output value 1.11 1.29 1.08 1.51 1.95

Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2016 2017 2018 2019 2020 2020 target
Glass Waste ton 11050.5 6209.9
Non-Hazardous Waste (Domestic Waste) tons 6311.3
Non-Hazardous Waste Disposed tons 80848 88967 85796.6 73538.6 36909.6
Total Non-Hazardous Waste Intensity (By Revenue) kg/RMB10000 55.27 48.01 34.43 25.74 16.26 38.69

Description of emissions target(s) set and steps taken to achieve them.

Standard Indicator Unit 2020
GHG Emissions Reduction Compared to Last Year tons 7399
NOx Emissions Reduction Compared to Last Year tons 308
SO2 Emissions Reduction Compared to Last Year tons 380

Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2016 2017 2018 2019 2020
Comprehensive Energy Consumption Intensity (By Revenue) GJ/RMB10000 of output value 4.43 3.51 3.11 2.65 2.53
Diesel Fuel Consumption litre 78886
Energy Consumption Intensity (By Revenue) GJ/RMB10000 of output value 4.43 3.51 3.11 2.65 2.53
Fossil Fuel Consumption ton 731881
Gasoline Consumption litre 132191
LPG Consumption kg 36665
Natural Gas Consumption m³ 18794063
Purchased Electricity kWh/year 47875186 51322112 655108860 631436019 637986028
Purchased Steam ton 731881
Total Direct Energy Consumption GJ/year 3281592 3839551 4466930 4344819 2604950
Total Energy Consumption GJ/year 5581931 6496683 7353262 7575550 7655768
Total Indirect Energy Consumption GJ/year 2500429 2657132 2368332 3231371 5050819

Water consumption in total and intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2016 2017 2018 2019 2020
Total Water Withdrawal m³/year 8769376 9515697 9959415 9527927 9381818
Wastewater Discharge Intensity tons/RMB10000 3.04 2.48 2.15
Water Consumption m³/year 8769376 9515697 9959415 9527927 9381818
Water Consumption Intensity (By Revenue) m³/RMB10000 5.99 5.14 3.99 3.33 3.1

Description of energy use efficiency target(s) set and steps taken to achieve them.

Standard Indicator Unit 2020
Electricity Usage Reduction Compared to Last Year kWh 228600
Steam Usage Reduction Compared to Last Year tons 5000

Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.

Standard Indicator Unit 2020
Wastewater Reduction Compared to Last Year tons 279921
Wastewater Reduction Percentage Compared to Last Year % -4.1

Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.

Standard Indicator Unit 2019 2020
Packaging Material Consumption (Metal) ton 468.4 352.7
Packaging Material Consumption (Paper) ton 10999.9 8550.1
Packaging Material Consumption (Plastic) ton 2715.3 1841
Packaging Material Consumption (Rubber) ton 854 468.1
Packaging Material Savings ton 3375
Packaging Materials Consumed ton 14886 20237
Packaging Materials Waste Recycled ton 19565.5
Usage of Packaging Materials (Wood) ton 181 2.24

Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.

Standard Indicator Unit 2016 2017 2018 2019 2020
Total Investment in Ecological Restoration RMB 3346000 7348000 15952000 12483000 12078600

Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.

Standard Indicator Unit 2018 2019 2020
Number of Bachelor's Degree Employees person 9137 10425 11329
Number of Below Junior College Employees person 8675 9230 8389
Number of Doctoral Degree Employees person 328 350 411
Number of Employees Aged 30-50 person 19732 21414 22412
Number of Employees Aged Above 50 person 8083 9916 9837
Number of Employees Aged Below 30 person 140 50 29
Number of Employees in Central China person 3853 4081 4718
Number of Employees in East China person 11094 12590 10637
Number of Employees in North China person 280 292 1249
Number of Employees in Northwest China person 1869 2584 2540
Number of Employees in Overseas person 4864 5326 5253
Number of Employees in South China person 4812 4929 5570
Number of Employees in Southwest China person 1293 1629 1879
Number of Female Employees person 13273 14830 15461
Number of Male Employees person 14972 16540 16797
Number of Master's Degree Employees person 2922 3312 3613
Number of Total Employees person 28245 31370 32258

Employee turnover rate by gender, age group and geographical region.

Standard Indicator Unit 2018 2019 2020
Percentage of Employees still Employed 12 Months after Return to Work (Female) % 100 100 100
Turnover Rate of Total Employees % 17.69 16.13 15.4

Lost days due to work injury.

Standard Indicator Unit 2016 2017 2018 2019 2020
Lost Days Due to Work-related Injuries hours 796
Lost Time Injury Frequency Rate (LTIFR/LTIR) per million man-hour 0.58 0.415 0.226 0.343 0.313

Description of occupational health and safety measures adopted, and how they are implemented and monitored.

Standard Indicator Unit 2016 2017 2018 2019 2020
Investment in Work Safety RMB'000 31550 39190 3843 5801 6186
Total Hours of Safety Training for Employees hours 237572 404227 434130

The percentage of employees trained by gender and employee category (e.g. senior management, middle management).

Standard Indicator Unit 2018 2019 2020
Percentage of Trained General Employees proportion 1 1 1
Percentage of Trained Senior Management proportion 1 1 1

The average training hours completed per employee by gender and employee category.

Standard Indicator Unit 2018 2019 2020
Average Training Hours (Female) hours/person 37 28 20
Average Training Hours (Male) hours/person 32 34 21
Average Training Hours per Employee hours/person 34 31 21
Total Training Hours man-hour 854993 993364 667561

Number of suppliers by geographical region.

Standard Indicator Unit 2020
Number of Suppliers in Hong Kong 10
Number of Suppliers in Mainland China 3182
Number of Suppliers in Overseas 308
Number of Total Suppliers 3500

Description of practices relating to observing and protecting intellectual property rights.

Standard Indicator Unit 2018 2019 2020
Number of Patents Applied 84 136 176
Number of Patents Granted 25 47 70

Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.

Standard Indicator Unit 2018 2019 2020
Number of Corruption Litigation items 215 264 247

Resources contributed (e.g. money or time) to the focus area.

Standard Indicator Unit 2020
Investment in Targeted Poverty Alleviation million RMB 3
Total Public Welfare Donations million RMB 40.38
Total Social Investment million RMB 40.38